A review of telavancin in the treatment of complicated skin and skin structure infections (cSSSI)

References

• BarriereSFGenterFEffects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjectsJ Clin Pharmacol2004446899515199073
   PubMed Web of Science ®Google Scholar
• BeauregardDAWilliamsDHDimerization and membrane anchors in extracellular targeting of vancomycin group antibioticsAntimicrob Agents Chemother19953978157793894
   PubMed Web of Science ®Google Scholar
• CDCStaphylococcus aureus resistant to vancomycin – United States, 2002MMWR Morb Mortal Wkly Rep2002a515657
   PubMedGoogle Scholar
• CDCVancomycin-resistant Staphylococcus aureus – Pennsylvania, 2002MMWR Morb Mortal Wkly Rep2002b51902
   PubMedGoogle Scholar
• ChambersHFThe changing epidemiology of Staphylococcus aureus?Emerg Infect Dis200177882
   Web of Science ®Google Scholar
• [CLSI] Clinical and Laboratory Standards InstitutePerformance Standards for Antimicrobial Susceptibility Testing; Seventeenth Informational Supplement M100-S172007 Volume, DOI
   Google Scholar
• CoreyRStryjewskiMTelavancin for the treatment of complicated skin and skin structure infections (cSSSI): results of the ATLAS I study200644th Infectious Disease Society of AmericaToronto, Canada
   Google Scholar
• DavisSLPerriMBEpidemiology and outcomes of community-associated methicillin-resistant Staphylococcus aureus infectionJ Clin Microbiol20074517051117392441
   PubMed Web of Science ®Google Scholar
• DraghiDJonesMThornsberryCTelavancin activity against current and diverse Staphylococcus aureus populations200545th Interscience Conference on Antimicrobial Agents and CemotherapyWashington D.C., USA
   Google Scholar
• DraghiDCBentonBMBaseline antistaphylococcal profile of telavancin: Results of the 2004–2005 US Surveillance Initiative200646th Annual ICAACSan Francisco, CA
   Google Scholar
• DrewRHEmerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infectionsPharmacotherapy2007272274917253914
   PubMed Web of Science ®Google Scholar
• DuchinKShawJSingle dose pharmacokinetics (PK) of telavancin (TLV) in healthy elderly subjects200414th European Congress of Clinical Microbiology and Infectious DiseasesPrague, Czech Republic
   Google Scholar
• FinegoldSMSongYClostridium clostridioforme: a mixture of three clinically important speciesEur J Clin Microbiol Infect Dis2005243192415891914
   PubMed Web of Science ®Google Scholar
• GoldsteinEJCitronDMIn vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic gram-positive species and Corynebacterium sppAntimicrob Agents Chemother20044821495215155214
   PubMed Web of Science ®Google Scholar
• GoossensHAntibiotic resistance: Highlights of the 16th European Congress on Clinical Microbiology and Infectious Diseases200616th European Congress on Clinical Microbiology and Infectious DiseasesNice, France
   Google Scholar
• HegdeSSReyesNPharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteriaAntimicrob Agents Chemother20044830435015273119
   PubMed Web of Science ®Google Scholar
• HershowRCKhayrWFCiprofloxacin resistance in methicillin-resistant Staphylococcus aureus: associated factors and resistance to other antibioticsAm J Ther199852132010099061
   PubMedGoogle Scholar
• HigginsDLChangRTelavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureusAntimicrob Agents Chemother20054911273415728913
   PubMed Web of Science ®Google Scholar
• HiramatsuKHanakiHMethicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibilityJ Antimicrob Chemother19974013569249217
   PubMed Web of Science ®Google Scholar
• HooperDCMechanisms of fluoroquinolone resistanceDrug Resist Updat19992385511504468
   PubMed Web of Science ®Google Scholar
• JansenWTVerelAIn vitro activity of telavancin against gram-positive clinical isolates recently obtained in EuropeAntimicrob Agents Chemother2007513420417606689
   PubMed Web of Science ®Google Scholar
• JevonsMCelbenin-resistant staphylococciBMJ196111245
   Web of Science ®Google Scholar
• JohnsonAPAuckenHMDominance of EMRSA-15 and -16 among MRSA causing nosocomial bacteraemia in the UK: analysis of isolates from the European Antimicrobial Resistance Surveillance System (EARSS) JAntimicrob Chemother2001481434
   Web of Science ®Google Scholar
• JudiceJKPaceJLSemi-synthetic glycopeptide antibacterialsBioorg MedChem Lett20031341658
   PubMed Web of Science ®Google Scholar
• LaohavaleesonSKutiJLTelavancin: a novel lipoglycopeptide for serious gram-positive infectionsExpert Opin Investig Drugs20071634757
   PubMed Web of Science ®Google Scholar
• LeadbetterMRAdamsSMHydrophobic vancomycin derivatives with improved ADME properties: discovery of telavancin (TD-6424)J Antibiot (Tokyo)2004573263615303493
   PubMed Web of Science ®Google Scholar
• LeuthnerKDCheungCMComparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureusJ Antimicrob Chemother2006583384316787952
   PubMed Web of Science ®Google Scholar
• LevineDPVancomycin: a historyClin Infect Dis200642Suppl 1S51216323120
   PubMed Web of Science ®Google Scholar
• MadrigalAGBasuinoLEfficacy of telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureusAntimicrob Agents Chemother2005493163516048918
   PubMed Web of Science ®Google Scholar
• MaorYRahavGPrevalence and characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a tertiary care centerJ Clin Microbiol2007451511417344363
   PubMed Web of Science ®Google Scholar
• MoelleringRCJrVancomycin: a 50-year reassessmentClin Infect Dis200642Suppl 1S3416323117
   PubMed Web of Science ®Google Scholar
• MoranGJKrishnadasanAMethicillin-resistant S. aureus infections among patients in the emergency departmentN Engl J Med20063556667416914702
   PubMed Web of Science ®Google Scholar
• NishimuraSTsurumotoTAntimicrobial susceptibility of Staphylococcus aureus and Staphylococcus epidermidis biofilms isolated from infected total hip arthroplasty casesJ Orthop Sci200611465016437348
   PubMed Web of Science ®Google Scholar
• OdenholtILowdinEPharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic modelAntimicrob Agents Chemother2007513311617620377
   PubMed Web of Science ®Google Scholar
• PatelJGrioMTelavancin pharmacokinetics during in vitro continuous venovenous hemodialysis2006a16th European Congress of Clinical Microbiology and Infectious DiseasesNice, France1539
   Google Scholar
• PatelJGrioMTelavancin transmembrane clearance during in vitro continuous venovenous hemofiltration2006b16th European Congress of Clinical Microbiology and Infectious DiseasesNice, France1538
   Google Scholar
• Pfizer2007 Accessed 23 June 2007 URL: http://www.pfizer.com
   Google Scholar
• ReyesNSkinnerREfficacy of telavancin in a murine model of bacteraemia induced by methicillin-resistant Staphylococcus aureusJ Antimicrob Chemother200658462516735425
   PubMed Web of Science ®Google Scholar
• ReyesNSkinnerREfficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureusAntimicrob Agents Chemother2005494344616189117
   PubMed Web of Science ®Google Scholar
• RiceLBAntimicrobial resistance in gram-positive bacteriaAm J Med2006119Suppl 1S119 discussion S62–7016735146
   PubMed Web of Science ®Google Scholar
• SakoulasGMoelleringRCJrAdaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapyClin Infect Dis200642Suppl 1S405016323119
   PubMed Web of Science ®Google Scholar
• SaravolatzLDPawlakJComparative activity of telavancin against isolates of community-associated methicillin-resistant Staphylococcus aureusJ Antimicrob Chemother200760406917586562
   PubMed Web of Science ®Google Scholar
• ShawJPSeroogyJPharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjectsAntimicrob Agents Chemother20054919520115616296
   PubMed Web of Science ®Google Scholar
• SpinkWFerrisVQuantitative action of penicillin inhibitor from penicillin-resistant strains in staphylococciScience1945102221317778506
   PubMed Web of Science ®Google Scholar
• StevensDLThe role of vancomycin in the treatment paradigmClin Infect Dis200642Suppl 1S51716323121
   PubMed Web of Science ®Google Scholar
• StryjewskiMEChuVHTelavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 studyAntimicrob Agents Chemother200650862716495243
   PubMed Web of Science ®Google Scholar
• StryjewskiMEO’RiordanWDTelavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteriaClin Infect Dis2005401601715889357
   PubMed Web of Science ®Google Scholar
• StyersDSheehanDJLaboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United StatesAnn Clin Microbiol Antimicrob20065216469106
   PubMedGoogle Scholar
• SunHKDuchinKTissue penetration of telavancin after intravenous administration in healthy subjectsAntimicrob Agents Chemother2006507889016436747
   PubMed Web of Science ®Google Scholar
• SwartzMNHospital-acquired infections: diseases with increasingly limited therapiesProc Natl Acad Sci USA199491242078146133
   PubMed Web of Science ®Google Scholar
• TalbotGHBradleyJBad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of AmericaClin Infect Dis2006426576816447111
   PubMed Web of Science ®Google Scholar
• Van BambekeFGlycopeptides in clinical development: pharmacological profile and clinical perspectivesCurr Opin Pharmacol20044471815351351
   PubMed Web of Science ®Google Scholar
• WongSShawJPenetration of telavancin into pulmonary epithelial lining fluid and alveolar macrophages200717th European Congress of Clinical Microbiology and Infectious DiseasesICC, Munich, Germany
   Google Scholar
• WongSShawJPPharmacokinetics of intravenous telavancin in subjects with hepatic impairment20062006 ICAAC MeetingSan Francisco, CA
   Google Scholar